Nashville, TNNCT07524855Now EnrollingIRB Ready

Metastatic Breast Cancer Clinical Trial in Nashville, TN

Access cutting-edge metastatic breast cancer treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Halda Therapeutics OpCo, Inc.

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access metastatic breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic breast cancer treatment provided free

Apply for This Nashville Location

Check if you qualify for this metastatic breast cancer clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Metastatic Breast Cancer Study in Nashville

Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

Sponsor: Halda Therapeutics OpCo, Inc.

Who Can Participate

Inclusion Criteria

Female (assigned at birth), ≥18 years old, and able to provide informed consent
Histologically confirmed metastatic or locally advanced breast cancer
Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
Prior treatment including at least one endocrine therapy in the metastatic setting, at least one CDK4/6 inhibitor (in the adjuvant and/or metastatic setting), and no more than two prior cytotoxic regimens in the metastatic setting
Radiologic disease progression on the most recent therapy
Measurable disease per RECIST v1.1
Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
ER-positive and HER2-negative status documented within 2 years
ECOG performance status 0-1 and life expectancy of at least 3 months
Adequate organ function Recovery from prior therapy-related toxicities to Grade ≤1 (except alopecia; neuropathy and endocrinopathies ≤Grade 2)
Ability to swallow oral medication and comply with study procedures
Stable dose (≥30 days) of bisphosphonates or denosumab, if applicable

Exclusion Criteria

Inflammatory breast cancer or known brain metastases
Recent major bleeding or uncontrolled bleeding disorder
Ongoing corticosteroid use \>10 mg/day (prednisone equivalent)
Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
Untreated or unstable spinal cord compression
Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
Major surgery within 28 days
Any condition that may interfere with safety or study compliance
Pregnancy or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT07524855) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Breast Cancer Treatment Options in Nashville, TN

If you're searching for metastatic breast cancer treatment options in Nashville, TN, this clinical trial (NCT07524855) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Nashville, TN

See all breast cancer clinical trials recruiting in Nashville — not just this study.

Browse Breast Cancer Trials in Nashville →

Browse More Trials by Condition

Breast Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN